

Our Business Segments

Endo International plc

Headquartered in Dublin, Ireland

\$4.0 billion

in revenue in 2016

+23%

from previous year

U.S. Generic Pharmaceuticals

Headquartered in Chestnut Ridge, New York

\$2.6 billion

in revenue in 2016

4th largest U.S. generics company based on market share. Develops, licenses, manufactures, markets and distributes safe, innovative and cost-effective pharmaceuticals with a focus on first-to-file or first-to-market opportunities and high-barrier-to-entry products that are difficult to formulate, difficult to manufacture, or that face complex legal and regulatory challenges. The generics R&D pipeline consists of over 200 products including approximately 120 ANDAs pending with the FDA.

Segment Milestones

- Completed generics restructuring and rationalized the generics portfolio and manufacturing network driving greater efficiency
- Launched approximately 20 new products including 2 key first-to-file products — quetiapine ER and ezetimibe
- Filed 27 regulatory submissions

Key Product Lines

Sterile products, New launches/Alternative Dosage Products, Base business

U.S. Branded Pharmaceuticals

Headquartered in Malvern, Pennsylvania

\$1.2 billion

in revenue in 2016

Focused on developing and marketing high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals' portfolio includes products for urology, men's health, orthopedics, endocrinology and hematology.

Segment Milestones

- Increased demand for XIAFLEX® in Peyronie's Disease and Dupuytren's Contracture with sales growing 20% in 2016
- Highly statistically significant Phase 2b data for XIAFLEX® in Cellulite
- Enhanced focus on our Specialty Branded Pharmaceuticals after returning BELBUCA™ to our partner and exiting promotion of pain medicines

Key Products

XIAFLEX®, SUPPRELIN® LA, TESTOPEL®, NASCOBAL®, AVEED®

International Pharmaceuticals

\$279 million

in revenue in 2016

Our International Pharmaceuticals businesses included: Paladin Labs, headquartered in Montreal, Canada; SOMAR, headquartered in Mexico City, Mexico; and Litha, headquartered in Midrand, South Africa.

Segment Milestones

- Paladin Labs secured Canadian rights to XIAFLEX® and launched the product in the fourth-quarter 2016
- Paladin Labs launched NUCYNTA® in the fourth-quarter 2016
- Initiated a sales process for Litha and related Sub-Saharan African business assets. The sale was announced in February 2017 and expected to close in the second-quarter 2017



By the Numbers

4,900

Endo has approximately 4,900 employees worldwide

\$4.01

Endo total 2016 revenue was \$4.01 Billion

250

U.S. Generic Pharmaceuticals has a portfolio of over 250 product families

200

U.S. Generic Pharmaceuticals has over 200 products in our pipeline including approximately 120 ANDAs currently under review with the FDA

20

U.S. Generics launched approximately 20 new products in 2016 including first-to-file quetiapine ER and ezetimibe tablets

+18%

U.S. Specialty Branded Pharmaceuticals performance +18% in 2016

\$190

XIAFLEX® achieved US sales of \$190 million, a 20% increase vs. prior year

30

Endo pursuing an indication for cellulite after Xiaflex demonstrated a highly statistically significant Ph2b data in cellulite; approximately 30 million women identified with self-reported cellulite